Evolent Health Inc (EVH)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Evolent Health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.10 $ — 11% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 88.1% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.20 | 0.13 – 0.26 | 2,502 | 117.4% | 9 |
| 12/31/2027 | 0.36 | 0.16 – 0.47 | 2,932 | 84.1% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.10 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.20 | – | 647 | 16.30 | -3.50 | -26 | -32 |
| 2025: Q1 | -0.56 | – | 484 | -24.40 | -13.40 | 5 | -4 |
| 2025: Q2 | -0.17 | -1,333.80 | 444 | -31.30 | -4.50 | -30 | -39 |
| 2025: Q3 | -0.18 | – | 480 | -22.80 | -4.40 | 16 | 7 |
| 2025: Q4 | -3.76 | – | 469 | -27.50 | -91.60 | 49 | 41 |
| 2026: Q1 | -0.24 | – | 496 | 2.60 | -5.40 | -1 | -7 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 254 | -237 | -160 | -3.55 | -36 | 912 | 1,200 |
| 2017 | 435 | -73 | -61 | -0.94 | -28 | 1,046 | 1,313 |
| 2018 | 627 | -47 | -53 | -0.68 | -21 | 1,189 | 1,722 |
| 2019 | 687 | -309 | -302 | -3.67 | -43 | 922 | 1,498 |
| 2020 | 925 | -263 | -334 | -3.94 | -16 | 620 | 1,474 |
| 2021 | 908 | -42 | -38 | -0.44 | 39 | 694 | 1,419 |
| 2022 | 1,352 | 4 | -19 | -0.20 | -12 | 859 | 1,817 |
| 2023 | 1,964 | -71 | -113 | -1.02 | 143 | 1,068 | 2,680 |
| 2024 | 2,555 | -40 | -62 | -0.54 | 19 | 1,001 | 2,544 |
| 2025 | 1,876 | -4 | -535 | -4.68 | 39 | 415 | 1,899 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Evolent Health, Inc. bietet über seine Tochtergesellschaft spezialisierte Versorgungsmanagement-Dienstleistungen in den Bereichen Onkologie, Kardiologie und Muskel-Skelett-Erkrankungen in den USA an.
| Employees | 4,200 |
|---|---|
| Headquarters | Arlington, VA |
| Address | 1812 N. Moore Street, 22209 Arlington, United States |
| Phone | 571 389 6000 |
| Website | evolent.com |
| IPO Date | 5. Jun 2015 |
| ISIN | US30050B1017 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Seth Barrie Blackley | Co-Founder, CEO & Director | 1979 |
| Dan McCarthy | President | 1985 |
| Jonathan David Weinberg J.D. | Chief Legal Officer, General Counsel & Secretary | 1968 |
| John Paul Johnson | Chief Strategy Officer | 1984 |
| Mario Marques Ramos | Chief Financial Officer | 1972 |
| Katie DiPerna Cook | Chief Operating Officer | – |
| Aammaad Shams | Chief Accounting Officer | 1984 |
| Robert Cruz | Chief Technology Officer | – |
| Jessica White | Chief Information Officer | – |
| John Tam M.D. | Chief Growth Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.